Matthew Kane - Precision BioSciences CEO, Co-Founder
DTIL Stock | USD 9.74 0.98 9.14% |
CEO
Mr. Matthew Kane is a Chief Executive Officer and CoFounder of the company . He has led the company since its inception in 2006 and serves on Precisions Board. He has nearly fifteen years of experience in the life sciences industry and was formerly with Suros Surgical Systems, later acquired by Hologic. When Matthew isnt working, you can find him enjoying time with his wife and daughters, hiking with his dogs, or stuck under a squat bar. He received his B.S. and M.S. from the RoseHulman Institute of Technology, and an MBA from Duke University.
Professional Marks | MBA |
Address | 302 East Pettigrew Street, Durham, NC, United States, 27701 |
Phone | 919 314 5512 |
Web | https://www.precisionbiosciences.com |
Precision BioSciences Management Efficiency
The company has return on total asset (ROA) of (0.1374) % which means that it has lost $0.1374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0726) %, meaning that it created substantial loss on money invested by shareholders. Precision BioSciences' management efficiency ratios could be used to measure how well Precision BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.46. The value of Return On Capital Employed is expected to slide to -0.42. At this time, Precision BioSciences' Fixed Asset Turnover is quite stable compared to the past year.Similar Executives
Found 12 records | CEO Age | ||
Joshua Brumm | Dyne TherapeuticsInc | 46 | |
Arnon Rosenthal | Alector | 68 | |
Amy MBA | Terns Pharmaceuticals | 53 | |
Robert Blum | Cytokinetics | 60 | |
Jeremy MBA | Day One Biopharmaceuticals | 53 | |
Daniel MBA | Acumen Pharmaceuticals | 53 | |
Mel MD | Galera Therapeutics | 67 | |
Mark Goldsmith | Revolution Medicines | 62 | |
William MD | Passage Bio | 50 | |
Denise ScotsKnight | Mereo BioPharma Group | 65 | |
Paula Ragan | X4 Pharmaceuticals | 54 | |
Robert Flexon | Dyne TherapeuticsInc | 57 |
Management Performance
Return On Equity | -1.07 | ||||
Return On Asset | -0.14 |
Precision BioSciences Leadership Team
Elected by the shareholders, the Precision BioSciences' board of directors comprises two types of representatives: Precision BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precision. The board's role is to monitor Precision BioSciences' management team and ensure that shareholders' interests are well served. Precision BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precision BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Maurissa Messier, Senior Communications | ||
Matthew Kane, CEO, Co-Founder | ||
Shalini Sharp, Director | ||
Drew Applefield, Director, Business Development | ||
Derek Jantz, Chief CoFounder | ||
Jefferson Smith, CoFounder Officer | ||
Bruce Stevens, Vice Compliance | ||
Raymond Schinazi, Director | ||
John Kelly, Chief Officer | ||
Juli Blanche, Chief Officer | ||
Garrett Gincley, Head Manufacturing | ||
Christopher Heery, Chief Medical Officer | ||
Mei Burris, Director Finance | ||
Cindy Atwell, Chief Officer | ||
John RPh, CFO Officer | ||
Alan MD, Chief Officer | ||
Heather King, Director PR | ||
Jeyaraj Antony, Research Scientist | ||
Michael Amoroso, CEO President | ||
Abid Ansari, CFO | ||
Shane Barton, Co VP | ||
Dario Scimeca, General Secretary |
Precision Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precision BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.07 | ||||
Return On Asset | -0.14 | ||||
Profit Margin | (1.26) % | ||||
Operating Margin | (2.12) % | ||||
Current Valuation | (11.27 M) | ||||
Shares Outstanding | 6.92 M | ||||
Shares Owned By Insiders | 8.47 % | ||||
Shares Owned By Institutions | 39.80 % | ||||
Number Of Shares Shorted | 288.87 K | ||||
Price To Earning | (6.10) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Precision BioSciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Precision BioSciences' short interest history, or implied volatility extrapolated from Precision BioSciences options trading.
Pair Trading with Precision BioSciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Precision BioSciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Precision BioSciences will appreciate offsetting losses from the drop in the long position's value.Moving against Precision Stock
0.41 | PFE | Pfizer Inc Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Precision BioSciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Precision BioSciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Precision BioSciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Precision BioSciences to buy it.
The correlation of Precision BioSciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Precision BioSciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Precision BioSciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Precision BioSciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Precision Stock analysis
When running Precision BioSciences' price analysis, check to measure Precision BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Precision BioSciences is operating at the current time. Most of Precision BioSciences' value examination focuses on studying past and present price action to predict the probability of Precision BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Precision BioSciences' price. Additionally, you may evaluate how the addition of Precision BioSciences to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Precision BioSciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (332.12) | Revenue Per Share 12.685 | Quarterly Revenue Growth (0.34) | Return On Assets (0.14) | Return On Equity (1.07) |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.